Medivation (NASDAQ:MDVN) +132.9% premarket after the company and its partner Astellas say their late-stage prostate cancer drug MDV3100 showed in a study that it could help the sickest patients live longer. Results were so positive that the study is being stopped early and men receiving placebo will be offered MDV3100 instead, the companies say.